AOBiome Therapeutics announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No. 3132021, with claims focused on its strain of beneficial AOB, in the class of Nitrosomonas eutropha.
The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.
The strain is delivered via a simple to use topical spray. Once deployed on the skin, AOB converts ammonia to nitrite, which is known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. It has also been demonstrated that this strain of AOB can reduce the inflammatory and pruritic cytokines, including IL-4, IL-5, IL-13, and IL-31 which are hallmarks of atopic response.
Related: Turn Bio's mRNA-based Platform Advances Skin Cell Rejuvenation
"Getting a composition of matter patent speaks to the unique aspects of this proprietary strain of AOB which has shown superior growth, stability and metabolic activity when compared to other strains. This coupled with our existing issued use patents for the entire class of AOB gives us a unique position in the marketplace" said AOBiome Therapeutics' President and CEO, Todd Krueger.
The company completed a Phase 2b study of 547 patients with mild-to-moderate atopic dermatitis and associated moderate-to-severe pruritus. B244 showed continued durability of treatment effect and separation from placebo post-treatment of 41.1% reduction in itch from baseline at eight weeks, four weeks after the last dose. This and other clinical trials have also demonstrated the unique safety profile of B244, with no treatment related SAE's reported on any of the over 1,000 patients that have participated in its trials.
The EP approval also provides patent coverage in Hong Kong. This patent follows on other related issued composition of matter patents in Japan, Canada, India and Australia. AOBiome has also been granted patents for the use of AOB on the treatment of acne, eczema, rosacea and psoriasis, along with other patents covering manufacturing, quality assurance and product delivery.
